Reviewing the mechanism of action and results of clinical studies on the antifungal drug ibrexafungerp

   Introduction. Vulvovaginal candidiasis is an extremely common pathology of the female genital organs, leading to a long-term recurrent course and multiple complications. Although currently it is widely known about developing antibiotic resistance of bacterial pathogens, it is necessary to remember about similar phenomenon observed in other groups of infectious agents. In this regard, fungal infection also requires development of new therapeutic techniques and medicinal antifungal drugs, such as ibrexafungerp.

   Aim: to analyze available publications revealing the mechanism of action, efficacy, antifungal spectrum and results of clinical trials for a new oral antifungal drug ibrexafungerp.

   Materials and Methods. A search for publications in the electronic databases PubMed, eLibrary and ClinicalTrials.gov, published over the last 25 years was conducted using the following keywords in Russian and English: “candidiasis”, “vulvovaginal candidiasis”, “antifungal drugs”, “ibrexafungerp”, “clinical trials”, “mechanism of action”. Articles were assessed according to PRISMA guidelines. The titles and abstracts of identified publications were independently reviewed to retrieve relevant full text studies. After the selection procedure, 46 articles were included in the review.

   Results. This review provides information on the creation of the drug ibrexafungerp, its mechanism of action, the activity against a relatively wide range of pathogens, as well as the results from 13 ongoing and completed clinical trials in patients with fungal infection.

   Conclusion. The analysis of ibrexafungerp-related clinical studies showed its good oral bioavailability, high antifungal efficacy, so that its one-day dosage may further eliminate a need for unnecessarily long hospitalization and complex dosing schedules, thereby increasing adherence to therapy and odds for treatment success.

1. Willems H.M.E., Ahmed S.S., Liu J. et al. Vulvovaginal candidiasis: a current understanding and burning questions. J Fungi (Basel). 2020;6(1):27. doi: 10.3390/jof6010027.

2. Gynecology: national guidelines. Eds. G.M. Savelyeva, G.T. Sukhikh, V.N. Serova, V.E. Radzinsky, I.B. Manukhina. [Ginekologiya: nacional'noe rukovodstvo. Pod red. G.M. Savel'evoj, G.T. Suhih, V.N. Serova, V.E. Radzinskogo, I.B. Manuhina]. Moscow: GEOTAR-Media, 2022. 1008 p. (In Russ.).

3. Khamad’yanova A.U., Zagidulina A.R., Zagretdinova D.R. et al. Prospects of human microbiome study for better understanding of ovarian cancer pathogenesis. [Perspektivy issledovaniya mikrobioma organizma cheloveka dlya luchshego ponimaniya patogeneza raka yaichnikov]. Rossiiskii vestnik akushera-ginekologa. 2023;23(1):39–46. (In Russ.). doi: 10.17116/rosakush20232301139.

4. Bairamova G.R., Amirkhanyan A.S., Chernova V.F. Vulvovaginal candidiasis: pathogenesis, diagnosis and treatment strategy. [Vul'vovaginal'nyj kandidoz: patogenez, diagnostika i taktika lecheniya]. https://journaldoctor.ru/. 2018;(10):32–6. (In Russ.). doi: 10.31550/1727-2378-2018-154-10-32-36.

5. Ziganshin A.M., Mulyukov A.R. Immunopathological mechanisms in sepsis of viral etiology in COVID-19. [Mekhanizmy immunopatologii sepsisa virusnoj etiologii pri COVID-19]. Sibirskoe medicinskoe obozrenie. 2021;(6):35–43. (In Russ.). doi: 10.20333/25000136-2021-6-35-43.

6. Ziganshin A.M., Keidar S.V., Khalitova R.Sh. et al. Human papillomavirus: etiology, pathogenesis, role, and importance in the development of cervical cancer : a review. [Virus papillomy cheloveka: etiologiya, patogenez, rol' i znachenie v razvitii raka shejki matki]. Ginekologiya. 2023;25(1):17–21. (In Russ.). doi: 10.26442/20795696.2023.1.202070.

7. Qin F., Wang Q., Zhang C. et al. Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis. Infect Drug Resist. 2018;11:1893–901. doi: 10.2147/IDR.S175588.

8. Je N.K., Youm S., Chun P. Real world co-prescribing contraindicated drugs with fluconazole and itraconazole. Pharmacoepidemiol Drug Saf. 2023;32(7):752–62. doi: 10.1002/pds.5604.

9. Apolikhina I.A., Bairamova G.R., Gomberg M.A. et al. Clinical guidelines for the diagnosis and treatment of diseases accompanied by pathological discharge from femal genital tract. [Klinicheskie rekomendacii po diagnostike i lecheniyu zabolevanij, soprovozhdayushchihsya patologicheskimi vydeleniyami iz polovyh putej zhenshchin]. Moscow: Rossijskoe obshchestvo akusherov-ginekologov, 2019. 57 p. (In Russ.).

10. Pappas P.G., Kauffman C.A., Andes D.R. et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. doi: 10.1093/cid/civ933.

11. Collins L.M., Moore R., Sobel J.D. Prognosis and long-term outcome of women with idiopathic recurrent vulvovaginal candidiasis caused by Candida albicans. J Low Genit Tract Dis. 2020;24(1):48–52. doi: 10.1097/LGT.0000000000000496.

12. Babic M., Hukic M. Candida albicans and non-albicans species as etiological agent of vaginitis in pregnant and non-pregnant women. Bosn J Basic Med Sci. 2010;10(1):89–97. doi: 10.17305/bjbms.2010.2744.

13. Mikamo H., Sato Y., Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother. 2000;46(3):485–7. doi: 10.1093/jac/46.3.485.

14. Denning D.W. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142–51. doi: 10.1016/S0140-6736(03)14472-8.

15. Peláez F., Cabello A., Platas G. et al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst Appl Microbiol. 2000;23(3):333–43. doi: 10.1016/s0723-2020(00)80062-4.

16. Onishi J., Meinz M., Thompson J. et al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother. 2000;44(2):368–77. doi: 10.1128/AAC.44.2.368-377.2000.

17. Apgar J.M., Wilkening R.R., Parker D.L. et al. Ibrexafungerp: an orally active β-1,3-glucan synthesis inhibitor. Bioorg Med Chem Lett. 2021;32:127661. doi: 10.1016/j.bmcl.2020.127661.

18. Davis M.R., Donnelley M.A., Thompson G.R. Ibrexafungerp: a novel oral glucan synthase inhibitor. Med Mycol. 2020;58(5):579–92. doi: 10.1093/mmy/myz083.

19. SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis. Available at: https://ir.scynexis.com/news-events/press-releases/detail/314/scynexis-announces-fda-approval-of-second-indication-for. [Accessed: 01. 05. 2023].

20. Garcia-Rubio R., de Oliveira H.C., Rivera J., Trevijano-Contador N. et al. The fungal cell wall: Candida, Cryptococcus, and Aspergillus species. Front Microbiol. 2020;10:2993. doi: 10.3389/fmicb.2019.02993.

21. Ghannoum M., Arendrup M.C., Chaturvedi V.P. et al. Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections. Antibiotics (Basel). 2020;9(9):539. doi: 10.3390/antibiotics9090539.

22. Hu X., Yang P., Chai C. et al. Structural and mechanistic insights into fungal β-1,3-glucan synthase FKS1. Nature. 2023;616(7955):190–8. doi: 10.1038/s41586-023-05856-5.

23. Xie J.L., Grahl N., Sless T. et al. Signaling through Lrg1, Rho1 and Pkc1 governs Candida albicans morphogenesis in response to diverse cues. PLoS Genet. 2016;12(10):e1006405. doi: 10.1371/journal.pgen.1006405.

24. Latgé J.P. The cell wall: a carbohydrate armour for the fungal cell. Mol Microbiol. 2007;66(2):279–90. doi: 10.1111/j.1365-2958.2007.05872.x.

25. Scorneaux B., Angulo D., Borroto-Esoda K. et al. SCY-078 is fungicidal against Candida species in time-kill studies. Antimicrob Agents Chemother. 2017;61(3):e01961–16. doi: 10.1128/AAC.01961-16.

26. Ghannoum M., Long L., Larkin E.L. et al. Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive Aspergillosis. Antimicrob Agents Chemother. 2018;62(6):e00244–18. doi: 10.1128/AAC.00244-18.

27. Park S., Kelly R., Kahn J.N. et al. Specific substitutions in the echino-candin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005;49(8):3264-73. doi: 10.1128/AAC.49.8.3264-3273.2005.

28. Marcos-Zambrano L.J., Gómez-Perosanz M., Escribano P. et al. The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp. J Antimicrob Chemother. 2017;72(7):1969–76. doi: 10.1093/jac/dkx010.

29. Garcia-Effron G., Lee S., Park S. et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009;53(9):3690–9. doi: 10.1128/AAC.00443-09.

30. Schell W.A., Jones A.M., Borroto-Esoda K. et al. Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species. Antimicrob Agents Chemother. 2017;61(11):e01102–17. doi: 10.1128/AAC.01102-17.

31. Pfaller M.A., Messer S.A., Rhomberg P.R. et al. Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species. Antimicrob Agents Chemother. 2017;61(8):e00161–17. doi: 10.1128/AAC.00161-17.

32. Berkow E.L., Angulo D., Lockhart S.R. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris. Antimicrob Agents Chemother. 2017;61(7):e00435–17. doi: 10.1128/AAC.00435-17.

33. Zhu Y.C., Barat S.A., Borroto-Esoda K. et al. Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int J Antimicrob Agents. 2020;55(4):105922. doi: 10.1016/j.ijantimicag.2020.105922.

34. Jiménez-Ortigosa C., Paderu P., Motyl M.R., Perlin D.S. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother. 2014;58(2):1248–51. doi: 10.1128/AAC.02145-13.

35. Astvad K.M.T., Hare R.K., Arendrup M.C. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. Clin Microbiol Infect. 2017;23(11):882–7. doi: 10.1016/j.cmi.2017.03.023.

36. Pfaller M.A., Messer S.A., Motyl M.R. et al. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother. 2013;57(2):1065–8. doi: 10.1128/AAC.01588-12.

37. Lamoth F., Alexander B.D. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother. 2015;59(7):4308–11. doi: 10.1128/AAC.00234-15.

38. Wring S., Murphy G., Atiee G. et al. Clinical pharmacokinetics and drug-drug interaction potential for coadministered SCY-078, an oral fungicidal glucan synthase inhibitor, and tacrolimus. Clin Pharmacol Drug Dev. 2019;8(1):60–9. doi: 10.1002/cpdd.588.

39. Wring S.A., Randolph R., Park S. et al. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother. 2017;61(4):e02068–16. doi: 10.1128/AAC.02068-16.

40. Wring S., Borroto-Esoda K., Solon E., Angulo D. SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14C]SCY-078 in albino and pigmented rats. Antimicrob Agents Chemother. 2019;63(2):e02119–18. doi: 10.1128/AAC.02119-18.

41. Lepak A.J., Marchillo K., Andes D.R. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015;59(2):1265–72. doi: 10.1128/AAC.04445-14.

42. Spec A., Pullman J., Thompson G.R. et al. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. J Antimicrob Chemother. 2019;74(10):3056–62. URL: https://pubmed.ncbi.nlm.nih.gov/31304536/.

43. Cadet R., Tufa M., Angulo D., Nyirjesy P. A Phase 2b, dose-finding study evaluating oral Ibrexafungerp vs Fluconazole in vulvovaginal candidiasis (DOVE). Obstet Gynecol. 2019;133(1):113S–114S. doi: 10.1097/01.AOG.0000558840.33387.ee.

44. Goje O., Sobel R., Nyirjesy P. et al. Oral Ibrexafungerp for vulvovaginal candidiasis treatment: an analysis of VANISH 303 and VANISH 306. J Women Health. 2023;32(2):178–86. doi: 10.1089/jwh.2022.0132.

45. Scynexis SCYNEXIS Announces Positive Top-Line Results from Its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection). SCYNEXIS. Available at: https://ir.scynexis.com/news-events/press-releases/detail/262/scynexis-pivotal-phase-3-vanish-306-trial-results-published. [Accessed: 01. 05. 2023].

46. Phillips N.A., Rocktashel M., Merjanian L. Ibrexafungerp for the treatment of vulvovaginal candidiasis: design, development and place in therapy. Drug Des Devel Ther. 2023;17:363–7. doi: 10.2147/DDDT.S339349.